Free tool
FAERS Monitor: Nemluvio
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761390 or its brand name (Nemluvio, Nemolizumab-Ilto). Reports on generic versions are filed under their own applications.
Reports
15,930
Serious
1,068
7% of reports
Hospitalization
479
Death reported
156
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue5,792
- device malfunction2,529
- pruritus1,581
- inappropriate schedule of product administration1,578
- incorrect dose administered1,544
- rash1,056
- drug ineffective947
- device use error658
- dermatitis atopic556
- headache505
- eczema420
- device leakage403
- arthralgia357
- dry skin349
- intentional product use issue343
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 2 |
| 2022 | 4 |
| 2023 | 6 |
| 2024 | 161 |
| 2025 | 7,279 |
| 2026 | 8,478 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,229 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device malfunctionSignal | 2,529 | 49.3 | 47.5 | 115,593 |
| product dose omission issueSignal | 5,792 | 26.5 | 26.0 | 141,320 |
| device use errorSignal | 658 | 25.5 | 23.6 | 15,174 |
| dermatitis atopicSignal | 556 | 14.1 | 13.0 | 6,677 |
| device leakageSignal | 403 | 12.4 | 11.2 | 4,173 |
| inappropriate schedule of product administrationSignal | 1,578 | 11.7 | 11.1 | 15,356 |
| eczemaSignal | 420 | 10.7 | 9.7 | 3,653 |
| incorrect dose administeredSignal | 1,544 | 9.0 | 8.6 | 10,994 |
| pruritusSignal | 1,581 | 5.5 | 5.2 | 5,823 |
| intentional product use issueSignal | 343 | 5.2 | 4.7 | 1,155 |
| dry skinSignal | 349 | 3.5 | 3.1 | 610 |
| rashSignal | 1,056 | 3.2 | 3.0 | 1,629 |
| arthralgia | 357 | 1.1 | 1.0 | 6 |
| headache | 505 | 1.1 | 1.0 | 2 |
| drug ineffective | 947 | 0.9 | 0.9 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.